Varda announces Series D to expand orbital pharmaceutical processing
Varda Space Industries →Varda announced a Series D financing led by Lux Capital and Natural Capital, with participation from Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital. The company said the financing would support a higher flight cadence and deeper pharmaceutical partnerships as it develops orbital processing capabilities. Its approach uses microgravity to explore crystal structures and drug formulations that differ from those produced under terrestrial conditions. President and Co-Founder Delian Asparouhov connected the financing to progress toward medicines manufactured in space for use on Earth. The release described development objectives and operating expansion, without establishing regulatory approval of any space-made medicine.